Antares Pharma Inc (NASDAQ:ATRS) received a $3.00 price objective from analysts at Piper Jaffray Companies in a research note issued to investors on Monday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target suggests a potential upside of 35.75% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on ATRS. Vetr cut Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 target price on the stock. in a report on Monday, June 26th. HC Wainwright set a $5.00 target price on Antares Pharma and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, ValuEngine cut Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $3.84.

Antares Pharma (NASDAQ:ATRS) traded up 1.38% during mid-day trading on Monday, hitting $2.21. 5,175,118 shares of the stock were exchanged. The company’s market capitalization is $345.66 million. Antares Pharma has a 1-year low of $1.41 and a 1-year high of $4.09. The stock has a 50 day moving average price of $3.04 and a 200 day moving average price of $2.97.

Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 27.89% and a negative net margin of 21.17%. The company had revenue of $13.42 million for the quarter, compared to analysts’ expectations of $12.99 million. On average, equities analysts anticipate that Antares Pharma will post ($0.11) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Antares Pharma Inc (ATRS) PT Set at $3.00 by Piper Jaffray Companies” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/antares-pharma-inc-atrs-pt-set-at-3-00-by-piper-jaffray-companies.html.

In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of ATRS. State Street Corp lifted its stake in Antares Pharma by 2,682.1% during the 2nd quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock valued at $6,530,000 after acquiring an additional 1,954,769 shares in the last quarter. Northern Trust Corp lifted its stake in Antares Pharma by 478.1% during the 2nd quarter. Northern Trust Corp now owns 1,654,266 shares of the specialty pharmaceutical company’s stock valued at $5,327,000 after acquiring an additional 1,368,131 shares in the last quarter. Rubric Capital Management LP lifted its stake in Antares Pharma by 34.4% during the 2nd quarter. Rubric Capital Management LP now owns 3,188,600 shares of the specialty pharmaceutical company’s stock valued at $10,267,000 after acquiring an additional 816,630 shares in the last quarter. Morgan Stanley lifted its stake in Antares Pharma by 153.3% during the 1st quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock valued at $2,829,000 after acquiring an additional 602,834 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Antares Pharma by 10.1% during the 2nd quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock valued at $19,920,000 after acquiring an additional 567,144 shares in the last quarter. Institutional investors and hedge funds own 36.77% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.